Superantigen mediated shock: a cytokine release syndrome.

Immunobiology

Institute of Medical Microbiology and Hygiene, Technical University of Munich, Germany.

Published: November 1993

Treatment of animals with superantigens results in profound immunological changes. A major fraction of all peripheral T cells becomes activated in vivo. Subsequently, successive waves of cytokines are produced with TNF playing a central pathophysiologic role. In addition, if the liver is damaged by an as yet poor defined mechanism the consequences of the cytokine syndrome are life threatening. However, TNF alone is not sufficient to cause death, instead synergizing interactions with cytokines like IL-1, IL-6, and IFN-gamma are probably involved. On the other hand, certain experimental conditions prevent these waves of cytokines and consequently lethal shock. Furthermore, a significant fraction of SA reactive T cells are deleted by programmed cell death 10 to 24 hours after treatment. Thereafter the surviving cells proliferate vigorously until day 2 or 3, followed by a second wave of apoptosis resulting in reduced SA reactive T cell numbers as compared to pretreatment levels. Of course, many aspects of the complicated events are only marginally understood and deserve further investigation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0171-2985(11)80362-1DOI Listing

Publication Analysis

Top Keywords

waves cytokines
8
superantigen mediated
4
mediated shock
4
shock cytokine
4
cytokine release
4
release syndrome
4
syndrome treatment
4
treatment animals
4
animals superantigens
4
superantigens profound
4

Similar Publications

The persistent emergence of COVID-19 variants and recurrent waves of infection worldwide underscores the urgent need for vaccines that effectively reduce viral transmission and prevent infections. Current intramuscular (IM) COVID-19 vaccines inadequately protect the upper respiratory mucosa. In response, we have developed a nonadjuvanted, interferon-armed SARS-CoV-2 fusion protein vaccine with IM priming and intranasal (IN) boost sequential immunization.

View Article and Find Full Text PDF

Therapeutic Ultrasound Modulates Cell Proliferation and Proinflammatory Cytokine Levels in Osteoarthritic Chondrocytes.

J Cell Mol Med

January 2025

Ataturk Vocational School of Health Services, Department of Medical Laboratory Techniques, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.

The development and progression of osteoarthritis (OA) are believed to involve inflammation. This study aimed to investigate the effects of applying therapeutic ultrasound (US) to human osteoarthritic chondrocytes in continuous and pulsed modes on cell proliferation and proinflammatory cytokine levels. Human osteoarthritic chondrocytes (HC-OA 402OA-05a) were proliferated in appropriate media and then seeded into culture plates.

View Article and Find Full Text PDF

Background: CD133 is regarded as a marker and target for cancer stem cells (CSCs) in various types of tumors, including hepatocellular carcinoma (HCC). The expressions of CD133 and programmed cell death ligand 1 (PD-L1) in CSCs exhibit a positive feedback regulatory effect. This effect promotes CSC proliferation and immune escape, ultimately leading to tumor progression and poor prognosis.

View Article and Find Full Text PDF

Characterization of focused ultrasound blood-brain barrier disruption effect on inflammation as a function of treatment parameters.

Biomed Pharmacother

January 2025

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address:

The technology of focused ultrasound-mediated disruption of the blood-brain barrier (FUS-BBB opening) has now been used in over 20 Phase 1 clinical trials to validate the safety and feasibility of BBB opening for drug delivery in patients with brain tumors and neurodegenerative diseases. The primary treatment parameters, FUS intensity and microbubble dose, are chosen to balance sufficient BBB disruption to achieve drug delivery against potential acute vessel damage leading to microhemorrhage. However, other safety considerations due to second order effects caused by BBB disruption, such as inflammation and alteration of neurovascular function, are only beginning to be understood.

View Article and Find Full Text PDF

Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child.

Int Immunopharmacol

January 2025

Department of Pediatrics, the First Medical Centre, Chinese PLA General Hospital, Beijing, China; Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, China; Medical School of Chinese People's Liberation Army, Beijing, China. Electronic address:

Febrile Infection-Related Epilepsy Syndrome (FIRES) is an infrequent yet severe form of epilepsy that rapidly evolves into status epilepticus following a febrile episode. Prompt diagnosis coupled with effective treatment strategies is critical for improving patient outcomes. Herein, we describe the case of an 11-year-old male with FIRES who was successfully treated with tocilizumab, resulting in no further seizures or residual disability.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!